SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

Core Viewpoint - SAB BIO is hosting a Research and Development webinar on January 28, 2025, to discuss topline data from the Phase 1 clinical trial of its lead candidate, SAB-142, aimed at delaying the onset or progression of type 1 diabetes (T1D) [1][4]. Company Overview - SAB BIO is a clinical-stage biopharmaceutical company focused on developing human, multi-targeted, high-potency immunoglobulins (IgGs) to treat and prevent immune and autoimmune disorders without the need for human donors or convalescent plasma [5]. - The lead asset, SAB-142, targets T1D with a disease-modifying therapeutic approach that aims to change the treatment paradigm by delaying onset and potentially preventing disease progression [5]. Webinar Details - The webinar is scheduled for January 28, 2025, at 8:00 AM ET, featuring presentations from SAB BIO's management and Dr. Michael Haller, a key opinion leader in diabetes research [2][4]. - A live question and answer session will follow the presentations, and a replay will be available on the SAB BIO website [2]. Phase 1 Trial Information - The Phase 1 trial for SAB-142 is a randomized, double-blind, placebo-controlled study designed to establish the safety, tolerability, pharmacokinetic, immunogenicity, and pharmacodynamic profile of the drug in healthy volunteers and participants with T1D [3].